TP53 and acute myeloid leukemia: TP53 mutations characterize a distinctive setting of AML associated with recurrent karyotypic aberrations, the lacking of recurrent single nucleotide mutations, dismal outcomes, and scarce responses to intensive therapeutic regimens.